The Cure Sickle Cell Initiative: Catalyzing Progress via Innovative Interfaces Between NIH, Patients, Academics, ASH, and the Private Sector
Dr. Edward Benz provides some background on the discovery of sickle cell disease and development of the Cure Sickle Cell Initiative. Dr. Ify Osunkwo adds further perspectiv
A New Standard of Care for Children and Young Adults With T-cell Acute Lymphoblastic Leukemia
Dr. Teachey reviews a study that shows outstanding outcomes for children and young adults with T-cell acute lymphoblastic leukemia that have raised the bar and established
Drs. Mehdi Hamadani, Mikkael Sekeres, and Martha Sola-Visner talk about exciting sessions and features available at the 60th ASH Annual Meeting in San Diego.
Dr. Parameswaran Hari discusses Sapiens, a compelling story of our species he believes every human could benefit from reading.
Dr. David Sallman sheds light on the profound negative connotation of TP53 mutation in myelodysplastic syndromes and the immediate need for effective biologically rational, targeted therapies.
November/December 2018Volume 15, Issue 6
View all Features articles
View all Diffusion articles
In her final President's Column, Dr. Thompson looks back at a year full of change and advancement, and provides a glimpse of what's to come in 2019 and beyond for ASH.
View all president's column articles
View all Ask the Hematologist articles
View all Clinical Trials Corner articles
View all Mini Review articles
ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.
In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.
In 2018, ASH commented on numerous rules and regulations proposed by the Centers for Medicare and Medicaid Services (CMS), which impact physician payment. ASH is actively involved in various advisory committees and also continues to engage with lawmakers on Capitol Hill.
During 2018, ASH continued to be highly visible in our advocacy for federal support of biomedical research and public health funding, including funding for the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC).
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology